These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 19164244

  • 21. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC.
    Cancer Res; 2002 Nov 01; 62(21):6146-51. PubMed ID: 12414640
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
    Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X.
    J Nucl Med; 2009 Jul 01; 50(7):1168-77. PubMed ID: 19525469
    [Abstract] [Full Text] [Related]

  • 24. Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy.
    Palner M, Shen B, Jeon J, Lin J, Chin FT, Rao J.
    J Nucl Med; 2015 Sep 01; 56(9):1415-21. PubMed ID: 26045308
    [Abstract] [Full Text] [Related]

  • 25. Preclinical evaluation of a dual sstr2 and integrin αvβ3-targeted heterodimer [68Ga]-NOTA-3PEG4-TATE-RGD.
    Liu B, Zhang Z, Wang H, Yao S.
    Bioorg Med Chem; 2019 Nov 01; 27(21):115094. PubMed ID: 31540828
    [Abstract] [Full Text] [Related]

  • 26. Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
    Ahmadi M, Sancey L, Briat A, Riou L, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP.
    Cancer Biother Radiopharm; 2008 Dec 01; 23(6):691-700. PubMed ID: 19111043
    [Abstract] [Full Text] [Related]

  • 27. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide.
    Edwards WB, Akers WJ, Ye Y, Cheney PP, Bloch S, Xu B, Laforest R, Achilefu S.
    Mol Imaging; 2009 Dec 01; 8(2):101-10. PubMed ID: 19397855
    [Abstract] [Full Text] [Related]

  • 28. (18) F labeled RGD-A7R peptide for dual integrin and VEGF-targeted tumor imaging in mice bearing U87MG tumors.
    Ma Y, Liang S, Guo J, Guo R, Wang H.
    J Labelled Comp Radiopharm; 2014 Sep 01; 57(11):627-31. PubMed ID: 25294311
    [Abstract] [Full Text] [Related]

  • 29. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
    Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, Boerman OC.
    J Nucl Med; 2014 Feb 01; 55(2):281-6. PubMed ID: 24408894
    [Abstract] [Full Text] [Related]

  • 30. Imaging tumor vasculature noninvasively with positron emission tomography and RGD peptides labeled with copper 64 using the bifunctonal chelates DOTA, oxo-DO3a. and PCTA.
    Yapp DT, Ferreira CL, Gill RK, Boros E, Wong MQ, Mandel D, Jurek P, Kiefer GE.
    Mol Imaging; 2013 Jun 01; 12(4):263-72. PubMed ID: 23651504
    [Abstract] [Full Text] [Related]

  • 31. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.
    Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M.
    J Nucl Med; 2005 Aug 01; 46(8):1333-41. PubMed ID: 16085591
    [Abstract] [Full Text] [Related]

  • 32. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin.
    Notni J, Steiger K, Hoffmann F, Reich D, Kapp TG, Rechenmacher F, Neubauer S, Kessler H, Wester HJ.
    J Nucl Med; 2016 Mar 01; 57(3):460-6. PubMed ID: 26635338
    [Abstract] [Full Text] [Related]

  • 33. Novel 64Cu Labeled RGD2-BBN Heterotrimers for PET Imaging of Prostate Cancer.
    Lucente E, Liu H, Liu Y, Hu X, Lacivita E, Leopoldo M, Cheng Z.
    Bioconjug Chem; 2018 May 16; 29(5):1595-1604. PubMed ID: 29587479
    [Abstract] [Full Text] [Related]

  • 34. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
    Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Mäcke HR, Eisenhut M, Debus J, Haberkorn U.
    J Nucl Med; 2005 May 16; 46(5):763-9. PubMed ID: 15872348
    [Abstract] [Full Text] [Related]

  • 35. Micro-positron emission tomography/contrast-enhanced computed tomography imaging of orthotopic pancreatic tumor-bearing mice using the αvβ₃ integrin tracer ⁶⁴Cu-labeled cyclam-RAFT-c(-RGDfK-)₄.
    Aung W, Jin ZH, Furukawa T, Claron M, Boturyn D, Sogawa C, Tsuji AB, Wakizaka H, Fukumura T, Fujibayashi Y, Dumy P, Saga T.
    Mol Imaging; 2013 Sep 16; 12(6):376-87. PubMed ID: 23981783
    [Abstract] [Full Text] [Related]

  • 36. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
    Li ZB, Chen K, Chen X.
    Eur J Nucl Med Mol Imaging; 2008 Jun 16; 35(6):1100-8. PubMed ID: 18204838
    [Abstract] [Full Text] [Related]

  • 37. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
    Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C, Myschetzky R, El-Ali HH, Madsen J, Kjaer A.
    Nucl Med Biol; 2014 Mar 16; 41(3):259-67. PubMed ID: 24417983
    [Abstract] [Full Text] [Related]

  • 38. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
    Shi J, Kim YS, Chakraborty S, Zhou Y, Wang F, Liu S.
    Amino Acids; 2011 Nov 16; 41(5):1059-70. PubMed ID: 20052508
    [Abstract] [Full Text] [Related]

  • 39. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
    Lopez-Rodriguez V, Gaspar-Carcamo RE, Pedraza-Lopez M, Rojas-Calderon EL, Arteaga de Murphy C, Ferro-Flores G, Avila-Rodriguez MA.
    Nucl Med Biol; 2015 Feb 16; 42(2):109-14. PubMed ID: 25316595
    [Abstract] [Full Text] [Related]

  • 40. Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice.
    Lo WL, Lo SW, Chen SJ, Chen MW, Huang YR, Chen LC, Chang CH, Li MH.
    Int J Mol Sci; 2021 May 21; 22(11):. PubMed ID: 34064291
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.